← Leaderboards
Uri Galili
Rush University Medical Center
$3,273,112
Attributed
$3,273,112
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $652.8K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$3,273,112 · 5
By mechanism
R01$2,180,648 · 3
R21$1,092,464 · 2
Top collaborators
No co-investigators on record.
Most similar at Rush University Medical Center
Same institution · by research overlap
- Kotaro Sena$149,250
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseInflammationCellsImmunoglobulinsImmune SystemAutologousImmunogenicErythrocytesEpitopesImmunoglobulin GGlycolipidsFutureImmunotherapyAntibodiesAffectBinding (Molecular Function)CeramidesChemotherapyCancer PatientCancer VaccinesAntigen-Presenting CellsCell MembraneFamily SuidaeInflammatory Response
Grant awards (12)
Intratumoral Injection of a-gal Glycolipids in Stage IV Melanoma: Phase I Trial$290,715
R21 · FY2011 · CA · contact PI
Xenograft-like rejection of tumors in a-gal glycolipids$337,188
R01 · FY2010 · CA · contact PI
Xenograft-like rejection of tumors in a-gal glycolipids$337,188
R01 · FY2009 · CA · contact PI
Intratumoral injection of a-gal glycolipids in stage IV melanoma: Phase I Trial$315,624
R21 · FY2009 · CA · contact PI
Xenograft-like rejection of tumors in a-gal glycolipids$337,188
R01 · FY2008 · CA · contact PI
INCREASE/gp120 IMMUNOGENICITY/LINKED ALPHA-GAL EPITOPES$243,125
R21 · FY2005 · AI
INCREASE/gp120 IMMUNOGENICITY/LINKED ALPHA-GAL EPITOPES$243,000
R21 · FY2004 · AI
PREVENTING ANTI-GAL PRODUCTION AGAINST XENOGRAFTS$253,750
R01 · FY2003 · AI
PREVENTING ANTI-GAL PRODUCTION AGAINST XENOGRAFTS$253,750
R01 · FY2002 · AI
PREVENTING ANTI-GAL PRODUCTION AGAINST XENOGRAFTS$251,709
R01 · FY2001 · AI
ENHANCING TUMOR VACCINE IMMUNOGENICITY BY ANTIGAL$206,962
R01 · FY2001 · CA
ENHANCING TUMOR VACCINE IMMUNOGENICITY BY ANTIGAL$202,913
R01 · FY2000 · CA